Biostem Technologies (BSEM) Stock Price

Biostem Technologies Inc is primarily active in the biotechnology and regenerative medicine industries.

Biostem Technologies Inc faces competition in the market from various companies. Some of the main competitors of Biostem Technologies Inc include Regenexx, RepliCel Life Sciences, Cytori Therapeutics, and Histogen. These companies, like Biostem Technologies Inc, are involved in the field of regenerative medicine and offer innovative solutions for various medical conditions. However, Biostem Technologies Inc differentiates itself through its unique proprietary technologies and expertise in stem cell research. It strives to stay ahead in the market by delivering cutting-edge solutions and maintaining a strong presence in the regenerative medicine industry.

Biostem Technologies Inc is a company with a rich history and background. It was founded in [year] and has since established itself as a leading player in the [industry] sector. The company focuses on [specific focus area], offering innovative solutions and services to its clients. Biostem Technologies Inc has experienced steady growth over the years, expanding its product portfolio and geographical presence. With its strong commitment to research and development, the company has continuously introduced cutting-edge technologies that have revolutionized the [industry] industry. Today, Biostem Technologies Inc remains a trusted name in the market, backed by a talented team and a solid track record of success.

Biostem Technologies Inc has achieved several significant milestones. One notable achievement is the development of innovative stem cell therapies for various medical conditions. The company has also successfully conducted clinical trials and obtained regulatory approvals for their products. In addition, Biostem Technologies Inc has established strategic partnerships with leading medical institutions and industry experts, further strengthening its position in the field. These accomplishments demonstrate the company's commitment to revolutionizing healthcare through advanced stem cell research and its dedication to improving patients' quality of life.

Biostem Technologies Inc is primarily present in the United States.

Biostem Technologies Inc represents innovative solutions in the field of regenerative medicine. With a strong focus on research and development, the company is dedicated to harnessing the power of stem cells and other advanced technologies to provide cutting-edge medical treatments. Biostem Technologies Inc places great emphasis on scientific excellence and strives to improve patients' quality of life by offering therapies that address various medical conditions. By upholding high standards of ethics and commitment to patient care, Biostem Technologies Inc positions itself as a trusted leader in the regenerative medicine industry.

7 analysts currently rate the Biostem Technologies stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Biostem Technologies to generate revenue of 28.74 M USD and earnings per share of -4.46 USD.

Biostem Technologies Analyst Price Targets 2026

Converted at the current exchange rate, the Biostem Technologies share trades at 1.48 EUR (1.66 USD).

Biostem Technologies Inc is a company that specializes in the development and distribution of medical devices and therapies. The company operates in three main areas: biomedical research, stem cell therapy, and regenerative medicine. In the field of biomedical research, Biostem Technologies Inc utilizes state-of-the-art technologies to gain fundamental scientific knowledge. The company aims to conduct groundbreaking research to develop new diagnostic procedures, drugs, and therapies that improve patients' quality of life. Another area in which Biostem Technologies Inc operates is stem cell therapy. The company focuses on optimizing the body's regenerative capacity and accelerating the healing of damaged organs and tissues. The company has developed a wide range of stem cell therapies that are intended to promote rapid restoration of human health. In regenerative medicine, Biostem Technologies Inc is involved in the development of advanced and innovative technologies to accelerate the healing process and promote the regeneration of organs and tissues. The goal is to help patients restore their health naturally, without relying on invasive procedures. The company offers a wide range of products and services tailored to the needs of various customers. These include biomedical devices, blood transfusion devices, and stem cell therapies. Biostem Technologies Inc also has its own website that serves as an online store where customers can conveniently order and purchase products from the comfort of their homes. In addition to the aforementioned business areas, Biostem Technologies Inc is also active in the research and development of products for the beauty industry. The company offers a wide range of products tailored to the needs of beauty enthusiasts and customers looking to improve their skincare. The range includes anti-aging creams, shampoos and conditioners for healthy hair, as well as nail care products. Overall, Biostem Technologies Inc is a leader in biomedical research, stem cell therapy, and regenerative medicine. The company is continuously striving to further develop its products and services to meet the needs of customers and improve patients' quality of life. With its innovative capabilities and customer-oriented strategies, the company continues to thrive in the medical and beauty industry.

The expected revenue of Biostem Technologies is 28.74 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Biostem Technologies is -41.23 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biostem Technologies is currently -0.37. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biostem Technologies stock.

The price-to-sales ratio (P/S) of Biostem Technologies is currently 0.53. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biostem Technologies stock.

The Eulerpool Quality Score for Biostem Technologies is 6/10.

The ISIN of Biostem Technologies is US0906842002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biostem Technologies is A14M3B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biostem Technologies is BSEM. The ticker symbol is used to trade Biostem Technologies shares on the stock exchange.